Logo

KVUE

Kenvue Inc.

KVUE

Kenvue Inc. • NYSE
$17.35 ▲ 0.75% (+0.13)
Market Cap $33.25 B
52w High $25.17
52w Low $14.02
Dividend Yield 0.82%
P/E 23.13
Volume 9.04M
Outstanding Shares 1.92B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.764B ▼ $1.597B ▲ $398M ▼ 10.574% ▼ $0.21 ▼ $760M ▼
Q2-2025 $3.839B ▲ $1.569B ▼ $420M ▲ 10.94% ▲ $0.22 ▲ $837M ▲
Q1-2025 $3.741B ▲ $1.61B ▲ $322M ▲ 8.607% ▲ $0.17 ▲ $701M ▲
Q4-2024 $3.662B ▼ $1.587B ▼ $293M ▼ 8.001% ▼ $0.15 ▼ $644M ▼
Q3-2024 $3.899B $1.628B $383M 9.823% $0.2 $855M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.139B ▲ $27.248B ▲ $16.614B ▲ $10.634B ▼
Q2-2025 $1.07B ▲ $27.132B ▲ $16.402B ▲ $10.73B ▲
Q1-2025 $1.057B ▼ $26.257B ▲ $16.204B ▲ $10.053B ▲
Q4-2024 $1.07B ▲ $25.601B ▼ $15.933B ▼ $9.668B ▼
Q3-2024 $1.057B $26.925B $16.281B $10.644B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $398M ▼ $294M ▼ $-104M ▼ $-110M ▲ $1.138B ▲ $196M ▼
Q2-2025 $420M ▲ $621M ▲ $-90M ▲ $-548M ▼ $-1.056B ▼ $533M ▲
Q1-2025 $322M ▲ $428M ▼ $-167M ▼ $-310M ▲ $-13M ▼ $249M ▼
Q4-2024 $293M ▼ $793M ▲ $-132M ▼ $-587M ▼ $13M ▼ $661M ▲
Q3-2024 $383M $249M $-56M $-162M $43M $190M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Essential Health
Essential Health
 $1.08Bn ▲$1.10Bn ▲$1.23Bn ▲$1.16Bn ▼
Self Care
Self Care
 $1.57Bn ▲$1.67Bn ▲$1.55Bn ▼$1.56Bn ▲
Skin Health and Beauty
Skin Health and Beauty
 $1.01Bn ▲$980.00M ▼$1.06Bn ▲$1.04Bn ▼

Five-Year Company Overview

Income Statement

Income Statement Kenvue’s sales have been steady, edging up slowly over the past few years rather than surging. This is typical of a mature consumer health and personal care business with well-known brands and broad distribution. Profitability, however, has moved in the opposite direction. Operating profit and net income have trended down from their earlier highs, and recent earnings are noticeably lower than a few years ago. This suggests pressure from higher costs, separation and setup expenses as a standalone company, and possibly heavier spending on marketing and innovation. Overall, the income statement shows a stable revenue base but some margin compression and weaker bottom-line performance compared with the pre‑spin period.

Balance Sheet

Balance Sheet The balance sheet shows a solid base of assets, but also a clear shift toward higher leverage after the spin-off from Johnson & Johnson. Debt jumped from very low levels a few years ago to a much more meaningful amount, while shareholders’ equity has come down. That means the company is now more reliant on borrowed money than it used to be within J&J. Cash on hand is modest relative to the size of the business, which is typical for a large, steady consumer products company but leaves less of a buffer for big shocks. The overall picture is a company with decent scale and asset backing, but a capital structure that now carries more financial risk than in the past and will require ongoing discipline around debt management.

Cash Flow

Cash Flow Kenvue generates healthy cash from its operations, reflecting the resilience of everyday consumer health and personal care products. Even in weaker profit years, the business has consistently brought in cash, and after routine investment in factories and equipment, it has still produced positive free cash flow. That said, cash flow was stronger in some past years than most recently, echoing the pressure seen in earnings. The company appears to be spending at a measured but consistent pace on capital projects, which is sensible for maintaining plants, innovation, and supply chain upgrades. Overall, cash flow remains a key strength, but the trend suggests less headroom than in the best historical years.

Competitive Edge

Competitive Edge Kenvue’s greatest strength is its portfolio of deeply trusted, everyday brands—names like Tylenol, Listerine, Neutrogena, Aveeno, and Johnson’s. These brands enjoy strong consumer loyalty, are widely available on shelves around the world, and can often command premium pricing. This gives the company a wide competitive moat and meaningful bargaining power with retailers. Its global scale adds to this advantage, allowing efficient manufacturing, marketing, and distribution across many countries. The flip side is that Kenvue operates in highly competitive categories where private labels and rival global brands constantly push on price and shelf space. The company’s brand equity and reach are clear strengths, but it must keep investing to prevent gradual erosion from competitors and retailer brands.

Innovation and R&D

Innovation and R&D Kenvue is putting noticeable emphasis on innovation, especially at the intersection of health, beauty, and technology. The partnership with Microsoft and the broader push into AI and data analytics show a desire to modernize how it develops products, understands consumers, and runs its operations. This includes using AI to improve formulations, optimize clinical research, and personalize consumer experiences. On the product side, the company is moving “beyond the pill” with offerings like the SmartCheck digital ear scope and various digital tools and apps. It is also backing its skincare and self-care brands with clinical studies and launching targeted new lines, from sensitive skin and collagen support to menopause-focused products. Sustainability is woven into the innovation process through tools that track environmental impact. The opportunity is significant, but there is execution risk: these digital and science-heavy initiatives need to translate into clear consumer adoption and lasting brand strength.

Summary

Kenvue looks like a classic, mature consumer health business with very strong brands and stable, global demand, but it is in the middle of an important transition. Revenues are steady rather than fast-growing, while profits and margins have softened compared with earlier years, likely reflecting higher costs, standalone company expenses, and heavier investment. The company’s balance sheet now carries more debt than it did inside Johnson & Johnson, increasing the importance of consistent cash generation and careful capital allocation. Cash flow remains a core strength, even if not at peak historical levels. Strategically, Kenvue is leaning hard into digital, AI, and science-backed innovation to protect and extend the life of its brands and to create new, more personalized health solutions. The long-term story hinges on two main questions: whether the company can restore and sustain stronger margins while managing its higher leverage, and whether its innovation and digital bets will keep its iconic brands relevant to younger and more demanding consumers. The foundations are strong, but execution over the next several years will be key to how the financial profile evolves.

NEWS

November 4, 2025 · 6:00 PM UTC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kenvue Inc. (NYSE: KVUE)

Read more

November 3, 2025 · 7:11 PM UTC

Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE

Read more

November 3, 2025 · 4:58 PM UTC

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.

Read more

November 3, 2025 · 1:30 PM UTC

KVUE Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Kenvue to Kimberly-Clark

Read more

November 3, 2025 · 11:14 AM UTC

Shareholder Alert: The Ademi Firm investigates whether Kenvue Inc. is obtaining a Fair Price for its Public Shareholders

Read more